New users of tyrosine kinase inhibitors (TKIs) who had heavily subsidized insurance with significantly lower out-of-pocket costs were more apt to be nonadherent, according to a study involving 836 individuals. Participants with Medicare Part D coverage had chronic myeloid leukemia and were prescribed TKIs for the first time. Investigators looked at the relationship between out-of-pocket costs per 30-day drug supply, Medicare Part D plan characteristics, and treatment adherence. Among the results:
- 3 of every 10 patients were nonadherent during the first 6 months of treatment.
- Patients with heavily subsidized coverage were nearly 7 times more likely to be nonadherent vs those without a subsidy.
- Patients who were moderately subsidized were 3 times more likely to be nonadherent.
Shen C, Zhao B, Liu L, Shih Y. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia. [Published online ahead of print October 4, 2017]. Cancer. doi:10.1002/cncr.31050.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al